{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:42:07Z","timestamp":1774316527923,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30801122"],"award-info":[{"award-number":["30801122"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","award":["2015ZSYXGG02"],"award-info":[{"award-number":["2015ZSYXGG02"]}],"id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006441","name":"Center for Outcomes Research and Evaluation, Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006441","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ebiom.2018.08.038","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T14:37:20Z","timestamp":1535553440000},"page":"46-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Purified CD34+ cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-Month results of a prospective randomised single-blinded non-inferiority trial"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3754-2458","authenticated-orcid":false,"given":"Zhihui","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5446-9945","authenticated-orcid":false,"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiejun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiguo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2018.08.038_bb0005","first-page":"142","article-title":"The fate of patients with critical leg ischemia","volume":"12","author":"Dormandy","year":"1999","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jvs.2010.08.060","article-title":"Treatment of peripheral arterial disease using stem and progenitor cell therapy","volume":"53","author":"Lawall","year":"2011","journal-title":"J Vasc Surg"},{"issue":"Suppl S","key":"10.1016\/j.ebiom.2018.08.038_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jvs.2012.03.255","article-title":"Update on clinical trials evaluating the effect of biologic therapy in patients with critical limb ischemia","volume":"56","author":"Powell","year":"2012","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0025","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(02)11977-5","article-title":"Peripheral-blood or bone-marrow mononuclear cells for therapeutic angiogenesis?","volume":"360","author":"Minamino","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/dmrr.2399","article-title":"Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment","volume":"29","author":"Dubsky","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0035","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1160\/TH07-02-0137","article-title":"Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans","volume":"98","author":"Huang","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0040","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/stem.207","article-title":"Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I\/IIa, multicenter, single-blinded, dose-escalation clinical trial","volume":"27","author":"Kawamoto","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0045","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1161\/CIRCINTERVENTIONS.112.968321","article-title":"Autologous CD34+ Cell Therapy for critical limb ischemia investigators. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia","volume":"5","author":"Losordo","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jvs.2013.01.037","article-title":"Transplantation of purified CD34+ cells in the treatment of critical limb ischemia","volume":"5","author":"Dong","year":"2013","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0055","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCRESAHA.111.253286","article-title":"Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity","volume":"109","author":"Sahoo","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0060","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1161\/CIRCULATIONAHA.106.644518","article-title":"CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells","volume":"114","author":"Kawamoto","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106310","article-title":"Cross talk with hematopoietic cells regulates the endothelial progenitor cell differentiation of CD34 positive cells","volume":"9","author":"Kwon","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0075","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","article-title":"Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0895-4356(98)00096-1","article-title":"Psychometric and clinical tests of validity of the Japanese SF-36 health survey","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/CIRCINTERVENTIONS.108.799361","article-title":"Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia","volume":"2","author":"Moriya","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0090","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/ten.tec.2014.0245","article-title":"Limb rescue: a new autologous-peripheral blood mononuclear cells technology in critical limb ischemia and chronic ulcers","volume":"21","author":"De Angelis","year":"2015","journal-title":"Tissue Eng Part C Methods"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0095","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1253\/circj.CJ-13-0864","article-title":"Phase II clinical trial of CD34+ cell therapy to explore endpoint selection and timing in patients with critical limb ischemia","volume":"78","author":"Fujita","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0100","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCULATIONAHA.105.589937","article-title":"Increase in vascular permeability and vasodilation are critical for proangiogenic effects of stem cell therapy","volume":"114","author":"You","year":"2006","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.ebiom.2018.08.038_bb0105","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1038\/ncpcardio0430","article-title":"Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI","volume":"3","author":"Shintani","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0110","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1161\/CIRCRESAHA.116.310557","article-title":"Angiogenicmechanisms of human CD34(+) stem cell exosomes in the repair of ischemic hindlimb","volume":"120","author":"Mathiyalagan","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0115","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/ATVBAHA.109.198895","article-title":"Clinical potential of adult vascular progenitor cells","volume":"30","author":"Kumar","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0120","first-page":"S255","article-title":"Identification of risk factors related to poor angiogenic potency of bone marrow cells from different patients","volume":"120","author":"Li","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2009.08.033","article-title":"Autologous stem cell therapy for peripheral arterial disease Meta-analysis and systematic review of the literature","volume":"209","author":"Fadini","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0130","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ahj.2008.06.025","article-title":"Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia","volume":"156","author":"Matoba","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0135","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1253\/circj.71.1187","article-title":"Effect of autologous bone marrow cell transplantation on ischemic ulcer in patients with Burger's disease","volume":"71","author":"Saito","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.atherosclerosis.2009.07.050","article-title":"Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mono- nuclear cells","volume":"208","author":"Horie","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCINTERVENTIONS.110.958348","article-title":"Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA)","volume":"4","author":"Walter","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0150","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.114.012913","volume":"131","author":"Teraa","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/sctm.17-0252","article-title":"A five-year study of the efficacy of purified CD34+ cell therapy for angiitis-induced no-option critical limb ischemia","author":"Fang","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0160","first-page":"1","article-title":"Thromboangiitis obliterans (Buerger's disease) \u2013 current practices","author":"Vijayakumar","year":"2013","journal-title":"Int J Inflam"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0165","first-page":"529","article-title":"Natural history of Buerger's disease","volume":"21","author":"Nielubowicz","year":"1980","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0170","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJM198305123081901","article-title":"Cellular sensitivity to collagen in thromboangiitis obliterans","volume":"308","author":"Adar","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02625113","article-title":"Clinical and radiologic aspects of Buerger's disease","volume":"7","author":"Hagen","year":"1984","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0180","first-page":"945","article-title":"Buerger disease, clinical prognostic aspects. 83 cases","volume":"22","author":"Dehaine-Bamberger","year":"1993","journal-title":"Presse Med"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0185","first-page":"695","article-title":"Diagnosis, pathology and treatment of Buerger's disease","volume":"75","author":"Shionoya","year":"1974","journal-title":"Surgery"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1172-1-14","article-title":"Thromboangiitis obliterans (Buerger's disease)","volume":"1","author":"Arkkila","year":"2006","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0195","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/CIRCRESAHA.116.309045","article-title":"Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies","volume":"120","author":"Rigato","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ebiom.2018.08.038_bb0200","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1358863X17752556","article-title":"Therapeutic efficacy of CD34(+) cell-involved mononuclear cell therapy for no-option critical limb ischemia: a meta-analysis of randomized controlled clinical trials","volume":"23","author":"Pan","year":"2018","journal-title":"Vasc Med"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239641830330X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239641830330X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:47:08Z","timestamp":1762454828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239641830330X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":40,"alternative-id":["S235239641830330X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.08.038","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purified CD34+ cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-Month results of a prospective randomised single-blinded non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}